Reference : Ipilimumab, a promising immunotherapy with increased overall survival in metastatic m...
Scientific journals : Article
Human health sciences : Dermatology
http://hdl.handle.net/2268/115638
Ipilimumab, a promising immunotherapy with increased overall survival in metastatic melanoma?
English
PIERARD, Gérald mailto [Centre Hospitalier Universitaire de Liège - CHU > > Dermatopathologie]
Aubin, Francois [Hôpital Saint Jacques, Besançon, France > > > > Dermatologie > >]
Humbert, Philippe [Hôpital Saint Jacques, Besançon, France > > > > Dermatologie > >]
2012
Dermatology Research and Practice
Hindawi Publishing Corporation
2012
182157
Yes (verified by ORBi)
International
1687-6105
1687-6113
Cairo
Egypt
[en] Malignant melanoma (MM) is one of the most aggressive skin cancer. The therapeutic options remain limited for advanced MM, and those directed to the neoplastic cells have not brought major survival advantage so far. Immunotherapy is another targeted option. Ipilimumab, a monoclonal antibody directed to CTLA-4 present on cytotoxic T cells boosts immunity, particularly its anti-MM activity. Under treatment, the overall survival of patients with MM metastases is moderately but significantly increased. The immuno-related adverse effects may be severe and life threatening.
http://hdl.handle.net/2268/115638
10.1155/2012/182157

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
IPILIMUMAB.pdfPublisher postprint86.81 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.